Eficácia e segurança de doravirina/islatravir para o HIV-1: uma revisão sistemática e meta-análise GRADE de ensaios controlados randomizados
InfectologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- HIV research & clinical practice
- Publicado em
- 4 jul 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Hamzah M. Alghzawi, Syed Zohad Shah, Zain Ul Abideen, Muhammad Farhan Ashraf
Descritores MeSH
- Anti-HIV Agents
- Pyridones
- Triazoles
- HIV-1
- HIV Infections
- Randomized Controlled Trials as Topic
- Treatment Outcome
- CD4 Lymphocyte Count
- Humans
Veja também
Estudos relacionados
- Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
- Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial
- Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
- Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
- Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis
- Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review